Developer docs
API playgroundTry for free, no card

Search company profiles

Peregrine Ventures

Full company profile

uuid0000gga

Namestring
Peregrine Ventures
Legal namestring
Peregrine Ventures Management Ltd.
Websiteurl
peregrinevc.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Peregrine Ventures is an Israeli venture capital firm founded in 2001 that operates as Israel's first dedicated healthcare investment platform. The firm manages three complementary vehicles spanning the company lifecycle: the Peregrine Incentive Incubator for pre-seed company formation, the Peregrine Ventures Fund for early- and mid-stage rounds, and the Peregrine Growth Fund for late-stage rounds. Across these vehicles, Peregrine has established 60 companies through its incubator program, of which 34 remain active, with an aggregate portfolio value of approximately $5B.

The firm's investment focus is healthcare and life sciences, including medical devices, biopharma, and digital health, anchored by strategic limited partner relationships with multinational pharmaceutical and medtech companies including Bristol-Myers Squibb, BD, Merck, Pfizer, AstraZeneca, and IBM, alongside Elbit Systems on the defense-biotech intersection. Peregrine benefits from a long-dated co-investment partnership with the Israel Innovation Authority, which matches up to 85% of early-stage investment over an eight-year horizon, materially de-risking seed-stage deployment.

The business model follows standard VC economics: management fees on committed and invested capital across the three funds, supplemented by carried interest on exits. Recent realized liquidity events include the sale of CartiHeal to Smith & Nephew (~$330M), BioProtect to Olympus (~$270M), CardioValve to Venus Medtech, and EndoStream to Kaneka. The firm maintains a small, partner-led operating team and has extended its geographic footprint beyond Israel into the United States, United Kingdom, and Singapore to source cross-border deals and follow-on capital.

Short descriptiontext

Peregrine Ventures is an Israeli healthcare-focused venture capital firm operating pre-seed, early/mid-stage, and late-stage funds, having built 60 companies with $5B aggregate portfolio value and strategic backing from major global pharma and medtech corporates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOr Yehuda, Israel
HQ citystring
Or Yehuda
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, life sciences investing, medical technology funding, healthtech venture capital, biotech private equity
Industry3 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAI
Healthcare Access & Life Sciences Impact Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management Fees
TypeManaged Services
Description

VC firms typically generate revenue through management fees charged on committed capital under management, typically ranging from 1.5-2.5% annually.

peregrinevc.com
2Carried Interest/Investment Returns
TypeLicensing Royalties
Description

Returns generated through successful exits of portfolio companies, including M&A transactions (CartiHeal acquired for $330M by Smith & Nephew, BioProtect acquired for $270M by Olympus, EndoStream acquired by Kaneka, CardioValve acquired by Venus Medtech) and IPOs (Neovasc, Eledon).

peregrinevc.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Peregrine Ventures is Israel's first dedicated healthcare venture capital fund, providing cross-stage equity investment and hands-on operational support to life sciences companies through three dedicated vehicles: the Incentive Incubator (pre-seed), the Peregrine Fund (early and mid-stage), and the Peregrine Growth Fund (late-stage pre-M&A/IPO). The firm invests across medical devices, pharma/biotech, and digital health, and provides portfolio companies with business development, regulatory navigation, team recruitment, and strategic alliance support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • The aggregate value of companies that have graduated from Incentive Incubator has reached $5 billion
+4 more records
Product overview1 text field

Peregrine Ventures is a venture capital firm offering three distinct investment vehicles for life science companies at different growth stages. The Incentive Incubator supports pre-seed companies with infrastructure, business development, and strategic planning; the Peregrine Fund targets early and mid-stage companies through development and regulatory phases; and the Peregrine Growth Fund assists mature companies in their final financing rounds before M&A or IPO. The firm does not offer a unified software product or platform—its offerings are financial investment vehicles, not technology products.

Product and service3 records
1Incentive Incubator
CategoryInvestment Vehicle
Description

Peregrine's technology incubator for pre-seed life sciences companies, providing technological infrastructure, financial management, business development support, strategic planning, and team recruitment assistance. Partners with pharma multinationals and research institutions. Has produced 60 companies with $5 billion aggregate value.

2Peregrine Fund (Early & Mid Stage)
CategoryInvestment Vehicle
Description

Investment vehicle providing capital and operational support to early and mid-stage life science companies, working closely with entrepreneurs during R&D, regulatory, reimbursement, and business operations phases.

3Peregrine Growth Fund
CategoryInvestment Vehicle
Description

Fund dedicated to mature companies in their final financing rounds prior to M&A or IPO, leveraging deep industry connections to facilitate successful exits at low risk with short time frames.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Bristol-Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Pharmaceutical multinational participating as a strategic investor in Peregrine's Incentive Incubator, supporting early-stage medical technology development alongside other major partners.

peregrinevc.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Medical devices company serving as a strategic investor in the Incentive Incubator consortium, contributing to the development of early-stage medical device companies.

3Elbit Systems
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Israeli defense contractor participating as a strategic investor in the Incentive Incubator, bringing defense technology expertise to medical technology development.

peregrinevc.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Global pharmaceutical company joined as strategic partner in the Incentive incubator, enhancing pharmaceutical and biotech investment capabilities. Also conducting mutual clinical trials with portfolio company Nectin Therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research institute partner in the Incentive Incubator, contributing academic research capabilities to early-stage company development.

6Ben-Gurion University of the Negev
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research institute partner providing scientific expertise and research capabilities to the Incentive Incubator ecosystem.

peregrinevc.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medical center partner contributing clinical research expertise to the Incentive Incubator alongside other prestigious research institutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Government authority that will match up to 85% of each early-stage investment by Incentive over eight years, significantly de-risking early-stage investments.

Strategic tierStrategicTypeTechnology or Integration
Description

Entered into licensing agreement with portfolio company Variantyx, providing AI technologies for somatic analysis to develop comprehensive tumor diagnostic solutions.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Launched pilot program with Cordio Medical's HearO app at Bellvitge University Hospital, testing voice analysis technology for heart failure monitoring.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Eyal Lifschitz of Peregrine Ventures co-hosts a panel at Biomed Israel's 24th annual forum, discussing convergence of medical devices, pharma, and software in healthcare.

Strategic tierStrategicTypeTechnology or Integration
Description

Portfolio company Nectin Therapeutics entered global license agreement granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed pioneering target.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israeli healthcare and life sciences venture capital firm investing across stages. Most direct competitor to Peregrine in the Israeli healthtech VC landscape with overlapping medical devices and digital health focus.

TypeDirect peer
Description

Israeli healthcare-dedicated venture capital firm investing in life sciences and biotech. Directly comparable to Peregrine's stage-agnostic Israeli healthcare investment thesis.

TypeDirect peer
Description

Israeli healthcare-focused investment firm with venture, growth, and pharma services arms. Operates cross-stage healthcare investments out of Israel similar to Peregrine.

TypeDirect peer
Description

Israeli medical device and digital health venture capital firm. Comparable to Peregrine's early-stage Israeli healthtech investment focus with global strategic LP partnerships.

TypeDirect peer
Description

Israeli healthcare-dedicated private equity and venture capital firm investing in medical devices and life sciences. Overlapping portfolio focus with Peregrine in Israeli medical technology.

TypeBroad incumbent
Description

Global healthcare-dedicated investment firm across venture, growth, and public equities. Broader scale and geographic reach than Peregrine but operates in the same healthcare VC category.

TypeBroad incumbent
Description

US-based early-stage life sciences venture capital firm. Comparable to Peregrine's early/mid-stage life sciences fund strategy with similar incubator-to-growth model.

TypeDirect peer
Description

Israeli venture capital firm with dedicated healthtech practice. Co-led the Restore Medical Series B with Peregrine and is a direct competitor in Israeli healthcare venture investing.

TypeRegional player
Description

Israeli venture capital firm with healthcare and life sciences portfolio exposure. Geographic peer with overlapping Israeli life sciences deal flow.

TypeBroad incumbent
Description

US healthcare-dedicated growth equity and venture capital firm. Comparable to Peregrine Growth Fund's late-stage healthcare investment thesis with similar medical device focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment240 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Peregrine Ventures

Healthcare Venture Capitalperegrinevc.com

Peregrine Ventures is an Israeli healthcare-focused venture capital firm operating pre-seed, early/mid-stage, and late-stage funds, having built 60 companies with $5B aggregate portfolio value and strategic backing from major global pharma and medtech corporates.

What Peregrine Ventures does

Peregrine Ventures is an Israeli venture capital firm founded in 2001 that operates as Israel's first dedicated healthcare investment platform. The firm manages three complementary vehicles spanning the company lifecycle: the Peregrine Incentive Incubator for pre-seed company formation, the Peregrine Ventures Fund for early- and mid-stage rounds, and the Peregrine Growth Fund for late-stage rounds. Across these vehicles, Peregrine has established 60 companies through its incubator program, of which 34 remain active, with an aggregate portfolio value of approximately $5B.

The firm's investment focus is healthcare and life sciences, including medical devices, biopharma, and digital health, anchored by strategic limited partner relationships with multinational pharmaceutical and medtech companies including Bristol-Myers Squibb, BD, Merck, Pfizer, AstraZeneca, and IBM, alongside Elbit Systems on the defense-biotech intersection. Peregrine benefits from a long-dated co-investment partnership with the Israel Innovation Authority, which matches up to 85% of early-stage investment over an eight-year horizon, materially de-risking seed-stage deployment.

The business model follows standard VC economics: management fees on committed and invested capital across the three funds, supplemented by carried interest on exits. Recent realized liquidity events include the sale of CartiHeal to Smith & Nephew (~$330M), BioProtect to Olympus (~$270M), CardioValve to Venus Medtech, and EndoStream to Kaneka. The firm maintains a small, partner-led operating team and has extended its geographic footprint beyond Israel into the United States, United Kingdom, and Singapore to source cross-border deals and follow-on capital.

Peregrine Ventures firmographics

Firmographics
Name
Peregrine Ventures
Legal name
Peregrine Ventures Management Ltd.
Website
https://peregrinevc.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
Peregrine Ventures is an Israeli healthcare-focused venture capital firm operating pre-seed, early/mid-stage, and late-stage funds, having built 60 companies with $5B aggregate portfolio value and strategic backing from major global pharma and medtech corporates.
Ownership category
akta.pro rank

Peregrine Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAJAI
Healthcare Access & Life Sciences Impact Funds
Financial & Insurance/Private Equity & Venture Capital/Impact / ESG & Sustainable Investment Funds

Keywords

  • Healthcare venture capital
  • Life sciences investing
  • Medical technology funding
  • Healthtech venture capital
  • Biotech private equity

Where Peregrine Ventures is headquartered

Location

Headquarters

HQ city
Or Yehuda
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Peregrine Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Fund Management Fees: VC firms typically generate revenue through management fees charged on committed capital under management, typically ranging from 1.5-2.5% annually.
  2. Carried Interest/Investment Returns: Returns generated through successful exits of portfolio companies, including M&A transactions (CartiHeal acquired for $330M by Smith & Nephew, BioProtect acquired for $270M by Olympus, EndoStream acquired by Kaneka, CardioValve acquired by Venus Medtech) and IPOs (Neovasc, Eledon).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Peregrine Ventures product offering

Product offering

Core offering

Peregrine Ventures is Israel's first dedicated healthcare venture capital fund, providing cross-stage equity investment and hands-on operational support to life sciences companies through three dedicated vehicles: the Incentive Incubator (pre-seed), the Peregrine Fund (early and mid-stage), and the Peregrine Growth Fund (late-stage pre-M&A/IPO). The firm invests across medical devices, pharma/biotech, and digital health, and provides portfolio companies with business development, regulatory navigation, team recruitment, and strategic alliance support.

Product overview

Peregrine Ventures is a venture capital firm offering three distinct investment vehicles for life science companies at different growth stages. The Incentive Incubator supports pre-seed companies with infrastructure, business development, and strategic planning; the Peregrine Fund targets early and mid-stage companies through development and regulatory phases; and the Peregrine Growth Fund assists mature companies in their final financing rounds before M&A or IPO. The firm does not offer a unified software product or platform—its offerings are financial investment vehicles, not technology products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Incentive Incubator Peregrine's technology incubator for pre-seed life sciences companies, providing technological infrastructure, financial management, business development support, strategic planning, and team recruitment assistance. Partners with pharma multinationals and research institutions. Has produced 60 companies with $5 billion aggregate value.
  • Peregrine Fund (Early & Mid Stage) Investment vehicle providing capital and operational support to early and mid-stage life science companies, working closely with entrepreneurs during R&D, regulatory, reimbursement, and business operations phases.
  • Peregrine Growth Fund Fund dedicated to mature companies in their final financing rounds prior to M&A or IPO, leveraging deep industry connections to facilitate successful exits at low risk with short time frames.

Quantifiable outcome

  • The aggregate value of companies that have graduated from Incentive Incubator has reached $5 billion
  • +4 more outcomes

Companies that use Peregrine Ventures

Customer profile

Segments3 records

Ideal customer profiles4 records

Peregrine Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Peregrine Ventures partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, strategic, major and supporting.

  • Bristol-Myers Squibb (BMS)coreStrategic or Co-development Partner · 1 January 2022Pharmaceutical multinational participating as a strategic investor in Peregrine's Incentive Incubator, supporting early-stage medical technology development alongside other major partners.
  • Becton Dickinson and Company (BD)coreStrategic or Co-development Partner · 1 January 2022Medical devices company serving as a strategic investor in the Incentive Incubator consortium, contributing to the development of early-stage medical device companies.
  • Elbit SystemscoreStrategic or Co-development Partner · 1 January 2022Israeli defense contractor participating as a strategic investor in the Incentive Incubator, bringing defense technology expertise to medical technology development.
  • MerckcoreStrategic or Co-development Partner · 1 January 2022Global pharmaceutical company joined as strategic partner in the Incentive incubator, enhancing pharmaceutical and biotech investment capabilities. Also conducting mutual clinical trials with portfolio company Nectin Therapeutics.
  • Tel Aviv UniversitycoreStrategic or Co-development PartnerResearch institute partner in the Incentive Incubator, contributing academic research capabilities to early-stage company development.
  • Ben-Gurion University of the NegevcoreStrategic or Co-development PartnerResearch institute partner providing scientific expertise and research capabilities to the Incentive Incubator ecosystem.
  • Shaare Zedek Medical CentercoreStrategic or Co-development PartnerMedical center partner contributing clinical research expertise to the Incentive Incubator alongside other prestigious research institutions.
  • Israel Innovation AuthoritycoreStrategic or Co-development PartnerGovernment authority that will match up to 85% of each early-stage investment by Incentive over eight years, significantly de-risking early-stage investments.
  • IBMstrategicTechnology or IntegrationEntered into licensing agreement with portfolio company Variantyx, providing AI technologies for somatic analysis to develop comprehensive tumor diagnostic solutions.
  • AstraZenecamajorStrategic or Co-development PartnerLaunched pilot program with Cordio Medical's HearO app at Bellvitge University Hospital, testing voice analysis technology for heart failure monitoring.
  • Biomed IsraelsupportingStrategic or Co-development PartnerEyal Lifschitz of Peregrine Ventures co-hosts a panel at Biomed Israel's 24th annual forum, discussing convergence of medical devices, pharma, and software in healthcare.
  • Immunome, Inc.strategicTechnology or IntegrationPortfolio company Nectin Therapeutics entered global license agreement granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed pioneering target.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Peregrine Ventures competitors and assessment

Company assessment

Direct peers

  • aMoon Fund: Israeli healthcare and life sciences venture capital firm investing across stages. Most direct competitor to Peregrine in the Israeli healthtech VC landscape with overlapping medical devices and digital health focus.
  • Pontifax Venture Capital: Israeli healthcare-dedicated venture capital firm investing in life sciences and biotech. Directly comparable to Peregrine's stage-agnostic Israeli healthcare investment thesis.
  • Arkin Holdings: Israeli healthcare-focused investment firm with venture, growth, and pharma services arms. Operates cross-stage healthcare investments out of Israel similar to Peregrine.
  • Triventures: Israeli medical device and digital health venture capital firm. Comparable to Peregrine's early-stage Israeli healthtech investment focus with global strategic LP partnerships.
  • Accelmed Partners: Israeli healthcare-dedicated private equity and venture capital firm investing in medical devices and life sciences. Overlapping portfolio focus with Peregrine in Israeli medical technology.
  • Pitango HealthTech: Israeli venture capital firm with dedicated healthtech practice. Co-led the Restore Medical Series B with Peregrine and is a direct competitor in Israeli healthcare venture investing.

Broad incumbents

  • OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equities. Broader scale and geographic reach than Peregrine but operates in the same healthcare VC category.
  • Atlas Venture: US-based early-stage life sciences venture capital firm. Comparable to Peregrine's early/mid-stage life sciences fund strategy with similar incubator-to-growth model.
  • Longitude Capital: US healthcare-dedicated growth equity and venture capital firm. Comparable to Peregrine Growth Fund's late-stage healthcare investment thesis with similar medical device focus.

Regional players

  • JVP (Jerusalem Venture Partners): Israeli venture capital firm with healthcare and life sciences portfolio exposure. Geographic peer with overlapping Israeli life sciences deal flow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Peregrine Ventures social profiles

Digital presence

Peregrine Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Peregrine Ventures leadership team

Management profile

Number of profiles

Profiles10 records

Peregrine Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Peregrine Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Peregrine Ventures M&A and investment

M&A and investment

M&A

Investments240 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peregrine Ventures

What does Peregrine Ventures do?

Peregrine Ventures is Israel's first dedicated healthcare venture capital fund, providing cross-stage equity investment and hands-on operational support to life sciences companies through three dedicated vehicles: the Incentive Incubator (pre-seed), the Peregrine Fund (early and mid-stage), and the Peregrine Growth Fund (late-stage pre-M&A/IPO). The firm invests across medical devices, pharma/biotech, and digital health, and provides portfolio companies with business development, regulatory navigation, team recruitment, and strategic alliance support.

Is Peregrine Ventures a public or private company?

Peregrine Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Peregrine Ventures founded?

Peregrine Ventures was founded in 2001. It employs 1 to 10 people.

Where is Peregrine Ventures based?

Peregrine Ventures is headquartered in Or Yehuda, Israel, in the Middle East region.

How does Peregrine Ventures make money?

Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest/Investment Returns.

Who are Peregrine Ventures's main competitors?

Direct peers on record are aMoon Fund, Pontifax Venture Capital, Arkin Holdings, Triventures, Accelmed Partners and Pitango HealthTech. Broad incumbents are OrbiMed Advisors, Atlas Venture and Longitude Capital. JVP (Jerusalem Venture Partners) is listed as a regional player.

Does Peregrine Ventures have an API?

No public API is recorded for Peregrine Ventures.

What industry is Peregrine Ventures in?

Peregrine Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In VivoBiomed 2026: From Device To Healthtech Via Software, Data And AIBiomed Israel will open its 24th annual forum on May 12 in Tel Aviv, bringing together the healthtech and life sciences ecosystem for three days to discuss the convergence of medical devices, pharma, and software. Eyal Lifschitz of Peregrine Ventures, who will co-host a panel featuring nine startups, notes that while Israeli innovators have faced a tough 2.5-year period, the sector has demonstrated resilience with companies maintaining business schedules. The panel session titled "The device is no longer a device" reflects how traditional healthcare product sector lines are increasingly blurred as digital, data, AI, and medical robotics integrate into healthcare delivery models.CTech“The same sensor fusion and computer vision tech used for military target acquisitionPeregrine Ventures' investor relations manager Amit Alfasi outlined how Israeli defense technology—particularly sensor fusion and computer vision originally developed for military target acquisition—is being adapted for healthcare and surgical robotics, with healthtech positioned as Israel's next major export engine after cybersecurity. The interview highlights portfolio companies including Biobeat, which recently recalibrated its go-to-market strategy following a funding round, and Snipe Medical, which anticipates FDA clearance in 2026 for its soft-tissue ablation system targeting solid tumors. The discussion frames Israeli tech as a mature, validated asset class for global limited partners, emphasizing the ecosystem's capital efficiency and operational resilience.PR NewswireKAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal CancerKAHR Bio announced topline Phase 2a results for DSP107 in combination with atezolizumab in late-line metastatic microsatellite stable colorectal cancer, demonstrating a median overall survival of 17.5 months versus 6.4–10.8 months for currently approved therapies, with approximately 75% of enrolled patients having liver metastases. The company also closed a $22 million equity financing round led by Flerie AB, Peregrine Ventures, Oriella Ltd., aMoon Growth Fund, Cancer Focus Fund, and SPRIM Global Investments, along with a $10 million on-demand debt facility, and initiated a randomized Phase 2b trial in December 2025 following FDA IND clearance.VcwirePeregrine Ventures Recognized as Israel’s Most Active Health Tech Investor in 2024Peregrine Ventures, an Israeli health tech investor, was ranked as Israel's most active health tech investor in 2024 on Startup Nation Central's map, with 15 investments. The firm manages about $600M and invested in companies like Variantyx, Insightec, and Kahr Medical across brain, cardiovascular, and oncology.PR NewswirePEREGRINE VENTURES CELEBRATES PORTFOLIO COMPANIES MILESTONE ACHIEVEMENTS IN Q1 2023Peregrine Ventures, an Israeli healthcare investment firm, announced Q1 2023 achievements across its portfolio companies, including a $25 million equity investment from Pfizer in Ribon Therapeutics and a clinical trial agreement between Nectin Therapeutics and Merck & Co. Additional milestones include successful Phase I/II clinical results from BioProtect's balloon implant system, FDA clearance for Levation Pharma's LEV102 treatment, and Restore Medical's positive first-in-human study results for the CONTRABAND transcatheter system. The firm also disclosed new early-stage investments in bio-convergence companies including OncoRedox, CTC Therapeutics, EViCure, and MilCo.WsjPeregrine Ventures Launches ‘Bioconvergence’ StartupsPeregrine Ventures, an Israel-based healthcare venture firm, launched four biomedical startups through its Incentive incubator. The startups combine technologies to detect and treat cancer and create animal-free dairy products. The incubator has created around 60 companies since 2002.BioWorldCordio raises $18M for heart failure detecting voice appCordio Medical Ltd. raised $18 million in venture funding from Ceros Capital Markets and Peregrine Ventures. The investment will support the company's Hearo voice app, which uses voice analysis to detect deterioration in patients with congestive heart failure. This funding round represents significant investor confidence in digital health technology for remote cardiac monitoring.PR NewswireCORDIO MEDICAL RAISES $18 MILLION IN FUNDING FROM CEROS AND PEREGRINE VENTURES TO ACCELERATE GROWTHCordio Medical raised $18 million in a strategic investment round led by Ceros Financial Services and Peregrine Ventures to support clinical studies, partnerships, and R&D for its HearO® CHF monitoring platform. The funding will facilitate the company's planned U.S. market entry in early 2024 pending final FDA approval.PR NewswirePEREGRINE VENTURES ANNOUNCES USD 300 MILLION EXIT FROM TRANSCATHETER MITRAL AND TRICUSPID VALVE REPLACEMENT COMPANY, CARDIOVALVE, BRINGING TOTAL PROCEEDS TO USD 1 BILLIONPeregrine Ventures, an Israeli healthcare investment firm, announced its USD 300 million exit from Cardiovalve, a transcatheter mitral and tricuspid valve replacement company, bringing total proceeds from both Cardiovalve and its predecessor Valtech Cardio to USD 1 billion. Cardiovalve was established as a spin-off following Valtech Cardio's sale to Edwards Lifesciences for USD 700 million in 2017, with Peregrine continuing to invest in and support the company through its development. The Cardiovalve System is currently undergoing clinical trials in Europe and early feasibility studies in the United States.DAICTechnology Incubator Peregrine Ventures Exits Transcatheter Valve Company CardiovalvePeregrine Ventures announced a $300 million exit from Cardiovalve, a medical device company developing transcatheter mitral and tricuspid valve replacement technologies. This transaction brings the total proceeds from Peregrine's investments in Cardiovalve and its predecessor Valtech Cardio to $1 billion. Following this exit, Cardiovalve will continue clinical trials for its valve systems in Europe and the United States.